קפרלסה 100 מ"ג

Ülke: İsrail

Dil: İbranice

Kaynak: Ministry of Health

Aktif bileşen:

VANDETANIB 100 MG

Mevcut itibaren:

ASTRA ZENECA ISRAEL LTD

ATC kodu:

L01XE12

Farmasötik formu:

FILM COATED TABLETS

Uygulama yolu:

PER OS

Tarafından üretildi:

ASTRA ZENECA UK LIMITED

Terapötik grubu:

VANDETANIB

Terapötik endikasyonlar:

Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. For patients in whom Rearranged during Transfection (RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision

Yetkilendirme tarihi:

2013-02-01